Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Climb Bio Inc (NASDAQ: CLYM) was $2.29 for the day, down -1.93% from the previous closing price of $2.33. In other words, the price has decreased by -$1.93 from its previous closing price. On the day, 0.62 million shares were traded. CLYM stock price reached its highest trading level at $2.41 during the session, while it also had its lowest trading level at $2.2.
Ratios:
Our analysis of CLYM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 14.08 and its Current Ratio is at 14.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on August 15, 2025, initiated with a Outperform rating and assigned the stock a target price of $9. On June 06, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $10.
On May 22, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $7.BTIG Research initiated its Buy rating on May 22, 2025, with a $7 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 30 ’25 when Brennan Aoife sold 20,618 shares for $1.22 per share. The transaction valued at 25,154 led to the insider holds 48,132 shares of the business.
Pimblett Emily sold 1,242 shares of CLYM for $1,540 on Jun 20 ’25. The SVP, Finance & CAO now owns 18,888 shares after completing the transaction at $1.24 per share. On Mar 20 ’25, another insider, Pimblett Emily, who serves as the SVP, Finance & CAO of the company, sold 1,199 shares for $1.31 each. As a result, the insider received 1,571 and left with 15,130 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLYM now has a Market Capitalization of 154840960 and an Enterprise Value of 70776968.
Stock Price History:
The Beta on a monthly basis for CLYM is -0.03, which has changed by -0.689538 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, CLYM has reached a high of $8.79, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 45.68%, while the 200-Day Moving Average is calculated to be 31.51%.
Shares Statistics:
CLYM traded an average of 468.77K shares per day over the past three months and 875300 shares per day over the past ten days. A total of 67.76M shares are outstanding, with a floating share count of 58.65M. Insiders hold about 13.46% of the company’s shares, while institutions hold 73.76% stake in the company. Shares short for CLYM as of 1755216000 were 1118221 with a Short Ratio of 2.39, compared to 1752537600 on 1382404. Therefore, it implies a Short% of Shares Outstanding of 1118221 and a Short% of Float of 3.08.
Earnings Estimates
The dynamic stock of Climb Bio Inc (CLYM) is currently being evaluated by a team of 4.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.13 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.7 and -$0.79 for the fiscal current year, implying an average EPS of -$0.74. EPS for the following year is -$0.75, with 4.0 analysts recommending between -$0.56 and -$0.93.
